A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination With Vinorelbine or Capecitabine in Women With ErbB2 Overexpressing Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2017
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms VITAL
- Sponsors GlaxoSmithKline; Novartis
- 02 Aug 2016 Status changed from active, no longer recruiting to completed.
- 03 Dec 2015 Planned End Date changed from 1 Sep 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 05 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History